摘要
目的:研究血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)患者血清中的表达及其与NSCLC疗效、组织病理类型、分期的关系。方法:收集符合入组条件的NSCLC患者60例,血清标本分别在化疗前和化疗2个周期后抽取,同时选取30例健康人血清做为对照组,应用酶联免疫吸附法测定VEGF含量。化疗采用NP方案。结果:NSCLC患者血清VEGF含量水平高于健康对照组,分别为(736.16±34.67)pg/ml和(197.22±36.40)pg/ml;NSCLC患者化疗前后血清VEGF水平分别为(736.16±34.67)pg/ml和(406.14±56.24)pg/ml,两者差异有统计学意义(P<0.01)。NSCLC患者治疗前血清中VEGF水平与临床分期相关,Ⅲ期和Ⅳ期NSCLC患者血清VEGF水平分别为(695.50±30.30)pg/ml和(815.95±36.85)pg/ml,两者差异有统计学意义(P<0.01),而与NSCLC肿瘤组织类型、年龄、性别、吸烟与否等无关。结论:NSCLC组血清VEGF表达水平明显高于健康人,化疗能够降低NSCLC患者血清VEGF表达,疗效不同的NSCLC患者化疗后VEGF变化趋势有所不同,治疗前血清VEGF含量与NSCLC临床分期相关。
Objective：To explore the correlation of the serum vascular endothelial growth factor with the effect, histological classification, TNM stage of non-small cell lung cancer （NSCLC）. Methods：Serum samples were obtained from NSCLC patients treated with chemotherapy in cancer center of central hospital of wafangdian from Jan 2005 to Dec 2006 before treatment and two cycles after treatment. The serum samples from healthy donors were used as controls. The concentration of VEGF in serum was measured with enzyme-linked immunosorbnent assay （ELISA）. Two courses of combined chemotherapy with vinorelbine and cisplatin were given. The difference in S-VEGF level between NSCLC patients and healthy donors and the changes in S-VEGF level before and after chemotherapy were observed and its correlation with histological classification, TNM stage of NSCLC was analyzed. Results：S-VEGF level was significandy higher in NSCLC patients than healthy controls [ （ 736. 16 ± 34.67 ） pg/ml and （ 197. 22 ± 36. 40 ） pg/ml, P 〈 0. 01 ]. Chemotherapy significantly reduced S-VEGF level （ P 〈 0. 01 ）. S-VEGF level before and after treatment were （ 736. 16±34. 67 ） pg/ml and （406. 14 ± 56. 24）pg/ml. The serum levels of VEGF in pretreatment NSCLC patients were closely related to the TNM stages. The serum concentration of VEGF in stage Ⅲand stage Ⅳ was 695.50 ±30. 30 and 815.95 ±36. 85. Conclusion：S-VEGF level is higher in the NSCLC patients than healthy controls. Chemotherapy could reduce S-VEGF level in NSCLC. The difference of S-VEGF level before treatment may be related to the TNM-stages of NSCLC.
出处
《临床肿瘤学杂志》
CAS
2007年第11期827-829,共3页
Chinese Clinical Oncology
